![](https://endpts.com/wp-content/uploads/2021/06/Hal-Barron-GSK-investor-day-3.png)
Hal Barron, GlaxoSmithKline R&D chief (GSK via investor day livestream)
GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug
GlaxoSmithKline’s R&D head Hal Barron has spent his four years on the job taking swing after swing to rejuvenate the drug giant’s pipeline after years …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.